Position of the Transparency Council – Actimodan (modafinil)
At its meeting on 27 January 2025, the Transparency Council adopted position No. 27/2025 on the evaluation of the drug Actimodan (modafinil) for the indication: Treatment of excessive sleepiness associated with narcolepsy with or without cataplexy in adults